biotech-now.org

Share

biotech-now.org

 •  September 15

This week the California Senate passed a tremendously flawed bill that would hamper the ability of entrepreneurs to bring new prescription medicines to California’s Senate Bill 17 is bad for patient & doesn’t deliver on promoting access to treatments & cures patients while threatening California’s leadership in biopharmaceutical innovation. This...

biotech-now.org

 •  August 22

It’s a refrain you hear often in the news: Drug costs are soaring and nothing is being done about it. But both claims have a tough time standing up to the facts. For starters, prescription drug spending and prices are actually remarkably stable. The Centers for Medicare and Medicaid Services reports that in 2016 prices grew by a modest 2.1 percent...

biotech-now.org

 •  July 18

“Safe prescription drugs.” That’s what pundits and politicians almost always promise when it comes to drug importation. But they almost always fail to mention the very real dangers patients would face when buying drugs from countries like China, India, and even Canada. At STATNews.com, BIO President and CEO Jim Greenwood explains what’s at stake if...

biotech-now.org

 •  July 7

Former President John Adams is known to have once said, “Facts are stubborn things,” and that’s certainly true when it comes to the drug cost debate. We know for a fact prescription drug spending continues to be remarkably stable, representing roughly the same share of total health care spending today (about 14 percent) as it did in 1960. We know...

biotech-now.org

 •  June 15

With a national debate underway over drug prices, people are looking for ways to help make prescription medicine more affordable. Unfortunately, many of the ideas drawing headlines are based on a faulty understanding of the drug cost ecosystem and would lead to negative consequences for patients. BIO is determined to set the record straight, and it...

biotech-now.org

 •  May 16

Yesterday, U.S. Representative Gus Bilirakis of Florida published an op-ed outlining how to “Lower Drug Costs Through Competition and Innovation.” Bilirakis writes that “leveraging the power of the free market and incentivizing competition among drug makers will drive costs down – not government mandates.” He cites the success of the Medicare Part...